

Printed as of 4/24/2024

# Disclosures

#### Personal Commercial (5)

| Company Name          | Relationship Category     | Compensation Level       | Topic Area(s)          |
|-----------------------|---------------------------|--------------------------|------------------------|
| Self                  |                           |                          |                        |
| Edwards Lifesciences  | Consultant Fees/Honoraria | Significant (>= \$5,000) | Valvular Heart Disease |
| GEN inCode            | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention             |
| Heart Valve Voice     | Consultant Fees/Honoraria | Significant (>= \$5,000) | Valvular Heart Disease |
| Medtronic             | Consultant Fees/Honoraria | Modest (< \$5,000)       | Other                  |
| Wilmington Healthcare | Consultant Fees/Honoraria | Modest (< \$5,000)       | Valvular Heart Disease |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (0)

No disclosures on record

#### Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (4)

| Year | Case Title                              | Represented | Description  | Compensation             |
|------|---|-------------|--|--------------------------|
| Self |   |             |  |                          |
| 2018 | Various Cardiac                         | Plaintiff   | UK law requires testimony to the Court, not on behalf of Plaintiff or Defendant.   | Significant (>= \$5,000) |
| 2017 | Miscellaneous expert<br>witness reports | Defendant   |  | Modest (< \$5,000)       |
| 2016 | Cardiology                              | Defendant   |  | Modest (< \$5,000)       |
| 2015 | Miscellaneous (UK only)                 | Defendant   | Provide medicolegal reports to the UK Court on various cases. Such expert advice is given to the Court (in the UK) and is therefore neither for defendant not plaintiff. | Significant (>= \$5,000) |

*†* Commercial Funding Source | *‡* Trial Name

## Agreement

## Certified Education Attestation | Signed on 4/1/2022

 ${\it URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement}}$ 

# Confidentiality, Disclosure and Assignment Agreement | Signed on 4/1/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

#### Embargo | Signed on 4/1/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 4/1/2022

#### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private

endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.